Trials / Unknown
UnknownNCT03200691
Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Hangzhou Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 3-DCRT or IMRT radiation | Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f. |
| DRUG | anti-PD-1 antibody SHR-1210 | SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes. |
Timeline
- Start date
- 2017-08-10
- Primary completion
- 2018-06-30
- Completion
- 2020-07-01
- First posted
- 2017-06-27
- Last updated
- 2017-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03200691. Inclusion in this directory is not an endorsement.